Halozyme Delivers Record Quarter, Raises Outlook, and Wins Wall Street Praise
Strong Q2 for Halozyme: Revenue $481M (+48% YoY), royalties +50%. Raises 2026 guidance. H.C. Wainwright, Leerink, Morgan Stanley upgrade.
/ 124 items
#XY Analyst Up/Down↓
Stifel Starts Sutro Biopharma at Buy With $48 Target on ADC Platform Potential
Stifel highlights ADC platform potential, dual-payload pipeline strength, near-term catalysts, and cash runway through 2028.
Black Diamond Therapeutics Shares Jump on Positive Silevertinib Phase 2 Data and Strong Cash Runway
Black Diamond Therapeutics reported Q2 results with robust silevertinib responses, no new brain mets, and cash expected to last into the second half of 2028.
Oppenheimer Upgrades Inspire Medical to Outperform with $85 Target After Q2 Beat
Company raises 2026 guidance and launches cost-cutting plan.
Wolfe Research Upgrades Madrigal to Outperform: Sees “Rare Opportunity” After Overdone Sell-Off
Wolfe Research views F4 data timing concerns as overblown after Madrigal’s Q2 beat and strong growth performance.
Leerink Upgrades Replimune to Outperform, Sees High Odds of FDA Approval for Melanoma Therapy
Leerink upgrades Replimune to Outperform with $17 target, citing high odds of FDA accelerated approval for RP-1 melanoma therapy after 10-3 vote.